Ensign Peak Advisors
SGTX

Ensign Peak Advisors’s Sigilon Therapeutics, Inc. Common Stock SGTX Stock Holding History

Ensign Peak Advisors’s Portfolio SGTX Stock Details SGTX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2021
Q3 		– Sell
-1,038
Closed -$145K – 1890
2021
Q2 		$145K Hold
1,038
– – ﹤0.01% 1753
2021
Q1 		$302K Buy
+1,038
New +$413K ﹤0.01% 1679

Other funds holding SGTX

FP
Flagship Pioneering Cambridge, Massachusetts $1.16B AUM 67.93% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Canada Pension Plan Investment Board
Canada Pension Plan Investment Board Toronto Ontario, Ontario, Canada $155B AUM 29.93% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
HP
Harbourvest Partners Boston, Massachusetts $101M AUM 38.13% 1-Year Est. Return
State of Wisconsin Investment Board
State of Wisconsin Investment Board Madison, Wisconsin $43.7B AUM 27.76% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
American Century Companies
American Century Companies Kansas City, Missouri $194B AUM 35% 1-Year Est. Return
MIM
Monashee Investment Management Boston, Massachusetts $184M AUM 197.43% 1-Year Est. Return

Ensign Peak Advisors's SGTX Position: Q3 2021 in Review

Ensign Peak Advisors sold out of Sigilon Therapeutics, Inc. Common Stock (SGTX) in Q3 2021, closing a stake of 1,038 shares — an estimated $145K sold.

Ensign Peak Advisors first reported a position in SGTX in Q1 2021 and held it in 2 quarters. The position peaked at $302K in Q1 2021. 45 funds tracked by Wall St. Rank hold SGTX as of Q3 2021.

  • Ensign Peak Advisors reported no remaining Sigilon Therapeutics, Inc. Common Stock position as of Q3 2021 after selling out during the quarter.
  • Ensign Peak Advisors sold 1,038 Sigilon Therapeutics, Inc. Common Stock shares in Q3 2021, an estimated $145K.
  • Ensign Peak Advisors first reported a position in Sigilon Therapeutics, Inc. Common Stock in Q1 2021 and held it in 2 quarters.
  • Ensign Peak Advisors's Sigilon Therapeutics, Inc. Common Stock position peaked at $302K in Q1 2021.
  • 45 funds tracked by Wall St. Rank held Sigilon Therapeutics, Inc. Common Stock as of Q3 2021.

Based on Ensign Peak Advisors's 13F filing for Q3 2021, filed 12 Nov 2021.